{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:05:26Z","timestamp":1792800326712,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002865","name":"Chongqing Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["CSTB2023NSCQ-MSX0424"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0424"]}],"id":[{"id":"10.13039\/501100002865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Municipal Health Commission Science-Health Collaborative Key Project","award":["2024ZDXM029"],"award-info":[{"award-number":["2024ZDXM029"]}],"id":[{"id":"https:\/\/ror.org\/04ce5fg13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15940-4","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:03:57Z","timestamp":1774847037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study"],"prefix":"10.1186","volume":"26","author":[{"given":"Haiping","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"14","key":"15940_CR1","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1002\/cncr.35301","volume":"130","author":"K Bielamowicz","year":"2024","unstructured":"Bielamowicz K, Dimitrion P, Abla O, Bomken S, Campbell P, Collin M, et al. Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures. Cancer. 2024;130(14):2416\u201339. https:\/\/doi.org\/10.1002\/cncr.35301.\u00a0","journal-title":"Cancer"},{"issue":"5","key":"15940_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/pbc.20884","volume":"48","author":"RD Alston","year":"2007","unstructured":"Alston RD, Tatevossian RG, McNally RJ, Kelsey A, Birch JM, Eden TO. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5):555\u201360. https:\/\/doi.org\/10.1002\/pbc.20884.\u00a0","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"15940_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, Sch\u00e4fer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175\u201384. https:\/\/doi.org\/10.1002\/pbc.24367.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"15940_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ped.12380","volume":"56","author":"A Morimoto","year":"2014","unstructured":"Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56(4):451\u201361. https:\/\/doi.org\/10.1111\/ped.12380.","journal-title":"Pediatr Int"},{"key":"15940_CR5","doi-asserted-by":"publisher","unstructured":"Stull MA, Kransdorf MJ, Devaney KO. Langerhans cell histiocytosis of bone. Radiographics: a review publication of the Radiological Society of North America, Inc. 1992;12(4):801\u2009\u2013\u200923. Epub 1992\/07\/01. https:\/\/doi.org\/10.1148\/radiographics.12.4.1636041.","DOI":"10.1148\/radiographics.12.4.1636041"},{"key":"15940_CR6","doi-asserted-by":"publisher","unstructured":"Windebank K, Nanduri V. Langerhans cell histiocytosis. Archives of disease in childhood. 2009;94(11):904-8. Epub 2009\/05\/22. https:\/\/doi.org\/10.1136\/adc.2007.125872.\u00a0","DOI":"10.1136\/adc.2007.125872"},{"issue":"4","key":"15940_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.survophthal.2008.04","volume":"53","author":"CE Margo","year":"2008","unstructured":"Margo CE, Goldman DR. Langerhans cell histiocytosis. Surv Ophthalmol. 2008;53(4):332\u201358. https:\/\/doi.org\/10.1016\/j.survophthal.2008.04.\u00a0","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"15940_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s13244-013-0271-7","volume":"4","author":"S Khung","year":"2013","unstructured":"Khung S, Budzik JF, Amzallag-Bellenger E, Lambilliote A, Soto Ares G, Cotten A, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights into imaging. 2013;4(5):569\u201379. https:\/\/doi.org\/10.1007\/s13244-013-0271-7.\u00a0","journal-title":"Insights into imaging"},{"issue":"11","key":"15940_CR9","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919\u201323. https:\/\/doi.org\/10.1182\/blood-2010-04-279083.\u00a0","journal-title":"Blood"},{"issue":"10","key":"15940_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","volume":"124","author":"NA Brown","year":"2014","unstructured":"Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655\u20138. https:\/\/doi.org\/10.1182\/blood-2014-05-577361.\u00a0","journal-title":"Blood"},{"issue":"4","key":"15940_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20130977","volume":"211","author":"ML Berres","year":"2014","unstructured":"Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211(4):669\u201383. https:\/\/doi.org\/10.1084\/jem.20130977.\u00a0","journal-title":"J Exp Med"},{"issue":"25","key":"15940_CR12","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","volume":"34","author":"S H\u00e9ritier","year":"2016","unstructured":"H\u00e9ritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of clinical oncology: official. J Am Soc Clin Oncol. 2016;34(25):3023\u201330. https:\/\/doi.org\/10.1200\/jco.2015.65.9508.","journal-title":"J Am Soc Clin Oncol"},{"issue":"4","key":"15940_CR13","doi-asserted-by":"publisher","first-page":"e33891","DOI":"10.1371\/journal.pone.0033891","volume":"7","author":"T Satoh","year":"2012","unstructured":"Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 2012;7(4):e33891. https:\/\/doi.org\/10.1371\/journal.pone.0033891.","journal-title":"PLoS ONE"},{"key":"15940_CR14","doi-asserted-by":"publisher","unstructured":"Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. The New England journal of medicine. 2018;379(9):856\u2009\u2013\u200968. https:\/\/doi.org\/10.1056\/NEJMra1607548.","DOI":"10.1056\/NEJMra1607548"},{"key":"15940_CR15","doi-asserted-by":"publisher","unstructured":"Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis: role of BRAF\/MAPK inhibition. Hematology American Society of Hematology Education Program. 2015;2015:565\u2009\u2013\u200970. https:\/\/doi.org\/10.1182\/asheducation-2015.1.","DOI":"10.1182\/asheducation-2015.1"},{"issue":"1","key":"15940_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","volume":"126","author":"CE Allen","year":"2015","unstructured":"Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26\u201335. https:\/\/doi.org\/10.1182\/blood-2014-12-569301.","journal-title":"Blood"},{"key":"15940_CR17","doi-asserted-by":"publisher","unstructured":"Abla O, Hematology American Society of Hematology Education Program. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease. 2023;2023(1):386\u2009\u2013\u200995. https:\/\/doi.org\/10.1182\/hematology.2023000439.\u00a0","DOI":"10.1182\/hematology.2023000439"},{"issue":"24","key":"15940_CR18","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.Ccr-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, et al. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I\/IIa Study. Clin cancer research: official J Am Association Cancer Res. 2019;25(24):7303\u201311. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2177.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"31","key":"15940_CR19","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/jco.19.00456","volume":"37","author":"J Donadieu","year":"2019","unstructured":"Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin oncology: official J Am Soc Clin Oncol. 2019;37(31):2857\u201365. https:\/\/doi.org\/10.1200\/jco.19.00456.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"15940_CR20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018651","author":"J Donadieu","year":"2026","unstructured":"Donadieu J, Evseev D, Pegoraro F, Sieni E, Slater O, Hutter C, et al. Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patients. Blood Adv. 2026. https:\/\/doi.org\/10.1182\/bloodadvances.2025018651.","journal-title":"Blood Adv"},{"issue":"3","key":"15940_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/14656566.2018.1429405","volume":"19","author":"M Minkov","year":"2018","unstructured":"Minkov M. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy. Expert Opin Pharmacother. 2018;19(3):233\u201342.","journal-title":"Expert Opin Pharmacother"},{"issue":"15","key":"15940_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.4103\/0366-6999.237400","volume":"131","author":"D Wang","year":"2018","unstructured":"Wang D, Cui L, Li ZG, Zhang L, Lian HY, Ma HH, et al. Clinical Research of Pulmonary Langerhans Cell Histiocytosis in Children. Chin Med J. 2018;131(15):1793\u20138. https:\/\/doi.org\/10.4103\/0366-6999.237400.","journal-title":"Chin Med J"},{"issue":"1","key":"15940_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4143\/crt.2020.769","volume":"53","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang D, Cui L, Ma HH, Zhang L, Lian HY, et al. Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis. Cancer Res Treat. 2021;53(1):261\u20139.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"15940_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5114\/pdia.2017.67095","volume":"35","author":"M Jezierska","year":"2018","unstructured":"Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M. Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy dermatologii i alergologii. 2018;35(1):6\u201317. https:\/\/doi.org\/10.5114\/pdia.2017.67095.\u00a0","journal-title":"Postepy dermatologii i alergologii"},{"issue":"1","key":"15940_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.21498","volume":"51","author":"A Guyot-Goubin","year":"2008","unstructured":"Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000\u20132004. Pediatr Blood Cancer. 2008;51(1):71\u20135. https:\/\/doi.org\/10.1002\/pbc.21498.\u00a0","journal-title":"Pediatr Blood Cancer"},{"key":"15940_CR26","doi-asserted-by":"publisher","unstructured":"Lin H, Batajoo A, Peckham-Gregory E, Zinn D, Eckstein OS, El-Mallawany NK et al. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025;146(2):206\u2009\u2013\u200918. https:\/\/doi.org\/10.1182\/blood.2024026671.","DOI":"10.1182\/blood.2024026671"},{"issue":"19","key":"15940_CR27","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007\u201315. https:\/\/doi.org\/10.1182\/blood-2014-05-577825.\u00a0","journal-title":"Blood"},{"key":"15940_CR28","doi-asserted-by":"publisher","unstructured":"Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, BRAF V600-mutated pediatric Langerhans cell histiocytosis. Dabrafenib, alone or in combination with trametinib, in. Blood advances. 2023;7(15):3806-15. https:\/\/doi.org\/10.1182\/bloodadvances.2022008414.","DOI":"10.1182\/bloodadvances.2022008414"},{"issue":"12","key":"15940_CR29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML, Hara J, Plant-Fox A, Aerts I, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023;389(12):1108\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2303815.\u00a0","journal-title":"N Engl J Med"},{"issue":"10","key":"15940_CR30","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.21037\/tp-2025-464","volume":"14","author":"Y Lu","year":"2025","unstructured":"Lu Y, Ye Y, Ren W, Leng X, Dai Y. Efficacy and safety of dabrafenib-targeted therapy for pediatric langerhans cell histiocytosis: a systematic review and meta-analysis. Translational Pediatr. 2025;14(10):2606\u201316. https:\/\/doi.org\/10.21037\/tp-2025-464.\u00a0","journal-title":"Translational Pediatr"},{"issue":"3","key":"15940_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell. 2015;28(3):370\u201383.","journal-title":"Cancer Cell"},{"issue":"2","key":"15940_CR32","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.chest.2022.10.003","volume":"163","author":"HT Lin","year":"2023","unstructured":"Lin HT, Wikenheiser-Brokamp KA, Udstuen G, Jones B, McCormack FX. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy. Chest. 2023;163(2):e53\u20136. https:\/\/doi.org\/10.1016\/j.chest.2022.10.003.\u00a0","journal-title":"Chest"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15940-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15940-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15940-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:51:03Z","timestamp":1778626263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15940-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15940"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15940-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the parents or legal guardians of all participating children. This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Medical Research Ethics Committee of the Children\u2019s Hospital of Chongqing Medical University (Approval No. (2025) Lun Shen (Lin Yan) Pi Jian No. (435)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details was obtained from legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"604"}}